NCT02829099View on ClinicalTrials.gov

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

July 1, 2021

Study Completion Date

July 29, 2021

Conditions
Advanced Solid Neoplasms
Interventions
DRUG

JNJ-64457107

JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.

Trial Locations (4)

Unknown

Haifa

Jerusalem

Tel Aviv

Madrid

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02829099 - A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Biotech Hunter | Biotech Hunter